| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Medical Billing - HA0 Record |
|
Advice You - Medical Billing - HA0 Record
In this installment on medical billing, we're going to review one of the shortest and yet one of the most confusing records for electronic billing of cla According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ims using NSF 3.01 specifications. This is the HA0 record. Curious as to what all the fuss is about? Keep reading and you'll find out. The HA0 record ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in doesn't really consist of very much. As a matter of fact, going over the individual fields is almost pointless. The first field is the standard record lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ype, which in this case is HA0. The second field is the sequence number in the claim, which we also see in all other records. The third field is the pa here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ient ID, which is in every record that transmits patient information. The fourth field is the line item control number, which in this case isn't even us d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ed yet. All that is new in this record is field five, which falls between positions 40 and 320. The field is labeled as extra narrative. So how much t ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ouble can this field possibly cause? To understand this, one must first understand the legal speak that goes along with the HA0 record. If you carefull easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi read the Medicare manual, it clearly states, for the description of this field, "Free form narrative record to submit additional information that may as nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ist in the adjudication of the service line item in the proceeding FA0 record". To further understand this description, one must first understand the re and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ason behind it as it is not clearly stated in the manual. The reason for this is very simple. Nobody is going to outright call a doctor or billing agen ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi y a crook. But like it or not, unethical billing practices do go on. Doctors prescribe treatments that are not needed and billers blindly go ahead and ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ill for them. This is nothing new. It has been going on for a long time. So in order to crack down on these unethical practices, the insurance carrier dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod are requiring extra narrative explanations in order to justify why a certain treatment is performed or a certain item is being given to a patient. Prob cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ably one of the biggest areas of fraud is with wheelchair claims. Patients are being given wheelchairs and these wheelchairs are being billed to Medicar tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen simply because the patient wants one, regardless of whether or not the patient really needs one. What constitutes need? This is a heated debate that w t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ll probably go on until the end of time. Some carriers say a patient must be totally unable to walk. Others say that the patient must have at least min ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust mum mobility. What is minimum mobility? That is the problem. Too many of these claims are open to interpretation. This is why extra narrative informa y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products tion is required so that the carrier can get a clearer picture of why the wheelchair, or other item is being prescribed. Is it a perfect system? No. B . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de t the HA0 record does help. Can this information also be fabricated? Of course. But at least billers and doctors now have to come up with good reasons elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip why the patient is getting the treatment being prescribed. In our next installment of medical billing, we'll cover another NSF 3.01 record specification tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Registered Office - Your Key to Credibility Valuation of Consulting Firms - A Blended Approach 3 Groups of People in the World
|